Aarti Drugs Ltd's Q3FY25 Quarter Results
- 30 Jan 2025
Result Summary
- Aarti Drugs Ltd reported a 5.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 6.4%.
- Its expenses for the quarter were down by 6.5% QoQ and 6.9% YoY.
- The net profit increased 6.1% QoQ and increased 1.0% YoY.
- The earnings per share (EPS) of Aarti Drugs Ltd stood at 4.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 568.50 | 599.81 | 607.61 | -5.2% | -6.4% |
Total Expenses | 517.74 | 553.93 | 556.06 | -6.5% | -6.9% |
Profit Before Tax | 50.76 | 45.88 | 51.55 | 10.6% | -1.5% |
Tax | 13.67 | 10.92 | 14.84 | 25.2% | -7.9% |
Profit After Tax | 37.09 | 34.96 | 36.71 | 6.1% | 1.0% |
Earnings Per Share | 4.10 | 3.80 | 4.00 | 7.9% | 2.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Aarti Drugs Ltd is a notable player in the pharmaceutical industry, primarily engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulations, and specialty chemicals. The company operates within the broader healthcare and chemicals sector, serving both domestic and international markets. Aarti Drugs is known for its extensive product portfolio that includes antibiotics, anti-protozoal, anti-inflammatory, and other therapeutic categories. As of the latest updates, the company has not disclosed any major developments, mergers, acquisitions, or strategic shifts in its operational focus. This report will focus on the financial performance of Aarti Drugs Ltd for the third quarter of fiscal year 2025.
Revenue
During the third quarter of fiscal year 2025, Aarti Drugs Ltd reported a total income of ₹568.50 crores. This represents a decline of 5.2% compared to the previous quarter (Q2FY25), where the total income was ₹599.81 crores, and a 6.4% decrease from the same quarter in the previous year (Q3FY24), which stood at ₹607.61 crores. The year-over-year comparison indicates a reduction in total income, suggesting potential impacts on revenue streams. This decrease in total income could be attributed to various factors, including market conditions, pricing strategies, or changes in demand for the company's products.
Profitability
For the third quarter of fiscal year 2025, Aarti Drugs Ltd's profit before tax was ₹50.76 crores, marking a 10.6% increase from the previous quarter's profit before tax of ₹45.88 crores. However, this is a slight decrease of 1.5% compared to the ₹51.55 crores profit before tax recorded in Q3FY24. The tax expense for the current quarter was ₹13.67 crores, which is an increase of 25.2% from the previous quarter but a 7.9% decrease year-over-year. Profit after tax for Q3FY25 was ₹37.09 crores, showing a 6.1% rise from Q2FY25 and a modest 1.0% increase from Q3FY24. Earnings per Share (EPS) for the quarter were ₹4.10, up 7.9% from the previous quarter and 2.5% higher compared to the same quarter last year, reflecting a slight improvement in profitability for shareholders.
Operating Metrics
The third quarter of fiscal year 2025 saw total expenses of ₹517.74 crores for Aarti Drugs Ltd, down 6.5% from the previous quarter's expenses of ₹553.93 crores and a 6.9% reduction from the expenses of ₹556.06 crores in Q3FY24. This reduction in expenses suggests operational efficiencies or cost-cutting measures that have been effective over both the quarter-on-quarter and year-over-year periods. The financial data indicates a strategic focus on managing operational costs, which might be contributing to the overall financial health of the company despite the decrease in revenue.
